Versione Italiana

SCHNITZLER SYNDROME (SS)

Luciano Schiazza M.D.
Dermatologist
c/o InMedica - Centro Medico Polispecialistico
Largo XII Ottobre 62
cell 335.655.97.70 - office 010 5701818
www.lucianoschiazza.it

SS is characterized by chronic, non pruritic recurrent  urticaria rash (pruritus is usually absent, especially at the disease onset. Lesions might become mildly pruritic in approx. 29% of patients after 3-4 years). The rash affects primarily the trunk and the extremities, sparing the palms, the soles and the head and neck areas. In some cases, it is triggered by ingestion of alcohol.

The urticarial rash consists of annular erythematous and macupapular pale-rose lesions of 0.5-3 cm diameter and sometimes confluent. Lesions last 12-36 hours and resolve completely, while new ones appear daily.

This first occurrence (it may not be followed by others for a long time) and other symptomatologic aspects help in defying the syndrome:

But the syndrome is characterized by:

Monoclonal gammophaty (IgM detectable with serum immunoelectrophoreisis).

Hematological screening often enhances:

Radiological screening:

The syndrome takes the name of the French dermatologist, Dott. Schnitzler, who first described it in1972.

The diagnosis is based on the combination of clinical, biological and radiological aspects that help differentiating SS from other similar conditions.

Therefore the characteristics of the syndrome are:

It is the disease of “open areas” and a major risk for people who stay or work in rural areas, especially from sundown to sunset.

To the above factors must be associated at least 2 of the above mentioned:

These classifying aspects are fundamental for the correct diagnosis, for other diseases may present overlapping symptoms, such as cutaneous eruptions, fever and articular pain and/or muscular: however there isn’t  monoclonal gammopathy IgM.

A few examples:

The exact pathogenesis of SS is unclear.

There isn’t a specific therapy.

Nonsteroidal anti-inflammatory drugs (NAIDs), corticosteroids immunosoppressive agents have been used with variable effects.

The IL-1 receptor antagonist Anakinra is today the treatment of choice.

The prognosis is related to the evolution because in 10-15% of patients lymphoplasmacytic malignancy developes more than 10-20 years after the first signs of the syndrome.